Search Results - Jag S. Lally

  • Showing 1 - 1 results of 1
Refine Results
  1. 1
    Cover Image

    Topical ruxolitinib 1.5% (JAK1/JAK2 inhibitor) improves clinical and patient‐reported outcomes in moderate to severe chronic hand dermatitis: Data from a small open‐label trial by Hannah D. Smith, Jag S. Lally, Alison Moy, Julie Ryan‐Wolf, Anna De Benedetto

    Published 2024
    Connect to this object online.
    Book

    Save to List
    Saved in:

Search Tools: